Hims & Hers Health (HIMS) posted a 21% profit decline in Q4 despite 28% revenue growth, with shares falling on mixed results and cautious guidance.
The telehealth platform’s earnings miss highlights margin pressure in a competitive digital health market, raising questions about profitability amid rapid expansion.
Key Takeaways
- Q4 profit dropped to 20.6 million from 26 million
- Revenue rose 28% to 617.8 million, meeting estimates
- Earnings per share of 0.08 beat analyst expectations
Market Reaction & Context
Hims & Hers shares declined in after-hours trading despite beating earnings per share expectations of 0.05 3. The mixed results reflect broader challenges facing telehealth companies as they balance growth investments with profitability demands.
The company’s revenue performance aligned with the digital health sector’s continued expansion, though margin compression signals intensifying competitive pressures in direct-to-consumer healthcare services.
Financial Performance
Net income fell to 20.6 million in the fourth quarter from 26 million in the prior-year period, while revenue climbed 28.4% to 617.81 million from 481.13 million 2. The revenue figure matched analyst estimates of 617.9 million 7.
For the full year 2025, the company reported 59% revenue growth with improved adjusted EBITDA metrics 8. However, the profit decline in Q4 overshadowed the strong top-line performance, contributing to investor disappointment.
Guidance and Outlook
The company provided what analysts described as “lukewarm” full-year guidance, with projected 2026 revenue slightly exceeding consensus estimates but Q1 2026 forecasts appearing conservative 5. Management’s cautious outlook reflects uncertainty in the telehealth regulatory environment and competitive landscape.
The mixed guidance comes after what sources described as “a tumultuous stretch” for the company 4, suggesting ongoing operational challenges despite strong revenue momentum.
Industry Implications
Hims & Hers’ results underscore the profitability challenges facing telehealth platforms as they scale operations. The disconnect between revenue growth and profit performance mirrors broader industry trends where companies prioritize market share over near-term margins.
The earnings report signals potential headwinds for the direct-to-consumer healthcare model, particularly as regulatory scrutiny increases and competition intensifies in key therapeutic areas.
Not investment advice. For informational purposes only.
References
1“Hims & Hers Health Fourth-Quarter Profit Falls Despite Higher Revenue”. The Wall Street Journal. Retrieved February 23, 2026.
2“Hims & Hers Health, Inc. Q4 Profit Drops”. RTTNews. Retrieved February 23, 2026.
3“Hims & Hers beats on Q4 earnings, shares down in line guidance”. Investing.com. Retrieved February 23, 2026.
4“Hims reports Q4 earnings beat, revenue miss”. Sherwood News. Retrieved February 23, 2026.
5“Hims & Hers Health (HIMS) Beats Q4 EPS Expectations”. GuruFocus. Retrieved February 23, 2026.
6“Earnings live: Hims & Hers stock slides, Domino’s rises as investors await crucial update from Nvidia”. Yahoo Finance. Retrieved February 23, 2026.
7“Hims & Hers Health’s (NYSE:HIMS) Q4 CY2025 Earnings Results”. Finviz. Retrieved February 23, 2026.
8“Hims & Hers posts 59% 2025 revenue growth, higher EBITDA”. StockTitan. Retrieved February 23, 2026.
9“Hims & Hers stock falls: Why earnings are underwhelming investors”. MSN. Retrieved February 23, 2026.